Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC | 8,453,038 | reported | 02 Feb 2026 | tx 20+11,392,515−7,188,585 |
| Akero Therapeutics, Inc. | 3,150,019 | reported | 06 Mar 2020 | tx 7−636,613 |
| Checkmate Pharmaceuticals, Inc. | 2,155,930 | reported | 16 May 2022 | tx 2−131,650 |
| PFIZER INC | 3,350 | reported | 30 Apr 2009 | tx 30+354,295 |
| RENOVIS INC | 0 | reported | 02 May 2008 | tx 215+797,439−1,601,040 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 02 Feb 2026 | PURCHASE | ALX ONCOLOGY HOLDINGS INC | 3,184,713 | 1.57 USD | first after silence |
| 20 Jan 2026 | GRANT_AWARD | ALX ONCOLOGY HOLDINGS INC | 40,400 | 0.00 USD | deriv |
| 21 Jan 2025 | GRANT_AWARD | ALX ONCOLOGY HOLDINGS INC | 40,400 | 0.00 USD | deriv |
| 13 Jun 2024 | GRANT_AWARD | ALX ONCOLOGY HOLDINGS INC | 20,200 | 0.00 USD | deriv |
| 20 Jun 2023 | GRANT_AWARD | ALX ONCOLOGY HOLDINGS INC | 20,200 | 0.00 USD | deriv |
| 15 Jun 2022 | GRANT_AWARD | ALX ONCOLOGY HOLDINGS INC | 12,004 | 0.00 USD | deriv |
| 13 May 2022 | SALE | Checkmate Pharmaceuticals, Inc. | 35,850 | 10.45 USD | |
| 16 May 2022 | SALE | Checkmate Pharmaceuticals, Inc. | 95,800 | 10.45 USD | anomaly |
| 11 Jun 2021 | GRANT_AWARD | ALX ONCOLOGY HOLDINGS INC | 12,004 | 0.00 USD | deriv |
| 21 Jul 2020 | CONVERSION | ALX ONCOLOGY HOLDINGS INC | 3,941,949 | — | |
| 21 Jul 2020 | CONVERSION | ALX ONCOLOGY HOLDINGS INC | 93,969 | — | |
| 21 Jul 2020 | CONVERSION | ALX ONCOLOGY HOLDINGS INC | 52,647 | — | |
| 21 Jul 2020 | PURCHASE | ALX ONCOLOGY HOLDINGS INC | 850,000 | 19.00 USD | |
| 21 Jul 2020 | CONVERSION | ALX ONCOLOGY HOLDINGS INC | 3,100,020 | — | |
| 21 Jul 2020 | CONVERSION | ALX ONCOLOGY HOLDINGS INC | 490,411 | — | deriv |
| 21 Jul 2020 | CONVERSION | ALX ONCOLOGY HOLDINGS INC | 3,100,020 | — | deriv |
| 21 Jul 2020 | CONVERSION | ALX ONCOLOGY HOLDINGS INC | 52,647 | — | deriv |
| 21 Jul 2020 | CONVERSION | ALX ONCOLOGY HOLDINGS INC | 15,794 | — | deriv |
| 21 Jul 2020 | CONVERSION | ALX ONCOLOGY HOLDINGS INC | 2,398,588 | — | deriv |
| 21 Jul 2020 | CONVERSION | ALX ONCOLOGY HOLDINGS INC | 1,052,950 | — | deriv |
| 21 Jul 2020 | CONVERSION | ALX ONCOLOGY HOLDINGS INC | 78,175 | — | deriv |
| 16 Jul 2020 | GRANT_AWARD | ALX ONCOLOGY HOLDINGS INC | 24,009 | 0.00 USD | deriv |
| 05 Mar 2020 | SALE | Akero Therapeutics, Inc. | 8,500 | 23.53 USD | |
| 04 Mar 2020 | SALE | Akero Therapeutics, Inc. | 35,650 | 23.81 USD | anomaly |
| 06 Mar 2020 | SALE | Akero Therapeutics, Inc. | 1,800 | 23.79 USD |
1 purchase reported after at least 12 months of silence — most recent on 02 Feb 2026.